Synonyms: compound 2 [PMID: 20151671] | EG-00229
Compound class:
Synthetic organic
Comment: EG00229 is a small molecule inhibitor of the binding of VEGF-A165 to its receptor neuropilin 1 (NRP1) [2]. It was originally developed to block neo-vascularisation in tumours. EG00229 has subsequently been used to confirm that NRP1 is a host binding factor for both SARS-CoV and SARS-CoV-2 [1]. It binds directly to the NRP1 domain that binds to the furin-cleaved S1 fragment of the viral spike protein, and by blocking this interaction EG00229 has been shown to reduce viral infection in in vitro systems.
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
References |
1. Cantuti-Castelvetri L, Ojha R, Pedro LD, Djannatian M, Franz J, Kuivanen S, van der Meer F, Kallio K, Kaya T, Anastasina M et al.. (2020)
Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity. Science, 370 (6518): 856-860. [PMID:33082293] |
2. Jarvis A, Allerston CK, Jia H, Herzog B, Garza-Garcia A, Winfield N, Ellard K, Aqil R, Lynch R, Chapman C et al.. (2010)
Small molecule inhibitors of the neuropilin-1 vascular endothelial growth factor A (VEGF-A) interaction. J Med Chem, 53 (5): 2215-26. [PMID:20151671] |